依奇珠单抗联合抗病毒治疗COVID-19的安全性与有效性:一项试点随机对照试验方案的结构化摘要
该试点随机对照试验分为两阶段:第一阶段开放治疗3例COVID-19患者,观察依奇珠单抗联合抗病毒治疗7天的安全性和有效性;第二阶段将40例患者按1:1随机分为依奇珠单抗联合抗病毒治疗组和单纯抗病毒治疗组,治疗14天。主要结局为肺CT严重程度评分的变化。
要点
- 依奇珠单抗联合抗病毒治疗可能减轻COVID-19免疫相关器官损伤。
- 第二阶段随机对照试验纳入40例IL-6升高的COVID-19患者。
- 主要结局为第7天、第14天或出院时肺CT严重程度评分变化。
核心结论
- 研究旨在探索依奇珠单抗联合抗病毒治疗COVID-19的安全性和有效性。
研究设计与样本
- 两阶段、两中心、开放标签、随机对照试点试验,第二阶段为2臂平行组设计(1:1)。
- 第一阶段开放治疗3例患者7天;第二阶段随机分组40例患者治疗14天。
关键数值与推荐
- 第一阶段:依奇珠单抗80 mg/ml,160 mg单次皮下注射,联合抗病毒治疗7天。
- 第二阶段:试验组依奇珠单抗160 mg单次皮下注射联合抗病毒治疗,对照组单纯抗病毒治疗,疗程14天。
- 抗病毒方案包括α-干扰素、洛匹那韦/利托那韦、氯喹、利巴韦林或阿比多尔,但不超过3种。
- 主要结局为肺CT严重程度评分变化,于第7天、第14天或出院时评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: A severe epidemic of COVID-19 has broken out in China and has become a major global public health event. We focus on the Acute Respiratory Distress Syndrome (ARDS)-like changes and overactivation of Th17 cells (these produce cytokines) in patients with COVID-19. We aim to explore the safety and efficacy of ixekizumab (an injectable drug for the treatment of autoimmune diseases) to prevent organ injury caused by the immune response to COVID-19. Ixekizumab is a human monoclonal antibody that binds to interleukin-17A and inhibits the release of pro-inflammatory cytokines and chemokines. TRIAL DESIGN: The experiment is divided into two stages. In the first stage, the open trial, 3 patients with COVID-19 are treated with ixekizumab, and the safety and efficacy are observed for 7 days. In the second stage, 40 patients with COVID-19 are randomly divided into two groups at 1:1 for 14 days. This is a two-center, open-label, randomized controlled pilot trial with 2-arm parallel group design (1:1 ratio). PARTICIPANTS: Patients with COVID-19 aged 18-75 with increased Interleukin (IL)-6 levels will be enrolled, but patients with severe infections requiring intensive care will be excluded. The trial will be undertaken in two centers. The first stage is carried out in Xiangya Hospital of Central South University, and the second stage is carried out simultaneously in the Third Xiangya Hospital of Central South University. INTERVENTION AND COMPARATOR: In the first stage, three subjects are given ixekizumab ("Taltz") (80 mg/ml, 160 mg as a single hypodermic injection) and antiviral therapy (α-interferon (administer 5 million U by aerosol inhalation twice daily), lopinavir/ritonavir (administer 100mg by mouth twice daily, for the course of therapy no more than 10 days), chloroquine (administer 500mg by mouth twice daily, for the course of therapy no more than 10 days), ribavirin (administer 500mg by intravenous injection two to three times a day, for the course of therapy no more than 10 days), or arbidol (administer 200mg by mouth three times a day, for the course of therapy no more than 10 days), but not more than 3 types). The treatment course of the first stage is 7 days. In the second stage, 40 randomized patients will receive the following treatments--Group 1: ixekizumab (80 mg/ml, 160 mg as a single hypodermic injection) with antiviral therapy (the same scheme as in the first stage); Group 2: antiviral therapy alone (the same scheme as in the first stage). The length of the second treatment course is 14 days. MAIN OUTCOMES: The primary outcome is a change in pulmonary CT severity score (an imaging tool for assessing COVID-19, which scores on the basis of all abnormal areas involved). Pulmonary CT severity score is assessed on the 7th day, 14th day, or at discharge. RANDOMISATION: In the second stage, 40 patients with COVID-19 are randomly divided into two groups at 1:1 for 14 days. The eLite random system of Nanjing Medical University is used for randomization. BLINDING (MASKING): The main efficacy indicator, the CT results, will be evaluated by the third-party blinded and independent research team. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): In the second stage, 40 patients with COVID-19 are randomly divided into two groups at 1:1 for 14 days. TRIAL STATUS: Trial registration number is ChiCTR2000030703 (version 1.7 as of March 19, 2020). The recruitment is ongoing, and the date recruitment was initiated in June 2020. The anticipated date of the end of data collection is June 2021. TRIAL REGISTRATION: The name of the trial register is the Chinese Clinical Trial Registry. The trial registration number is ChiCTR2000030703 ( http://www.chictr.org.cn/ ). The date of trial registration is 10 March 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting the dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).
引用
- Liu P, Huang Z, Yin M, et al. Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial. Trials. 2020. PMID: 33276811. doi:10.1186/s13063-020-04925-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。